A randomized phase II study of paclitaxel (P), carboplatin (C), bevacizumab (B) +/- everolimus (E) in metastatic melanoma (MM): secondary analysis of outcomes in patients who harbor an NRAS mutation NCCTG N0879 (Alliance). Kottschade, Lisa , Allred, Jacob , Rumila, K. , Markovic, Svetomir ... - SMR - - 2017 Abstract - Secondary - Primary - Experimental - N0879
Cell Free DNA BRAF Mutation V600 Plasma Detection in Melanoma (Alliance) NCCTG N0879 Slostad, Jessica , Allred, Jake , Markovic, Svetomir , Erickson, Lori ... - SMR - Pigment Cell & Melanoma Research - 2018 Abstract - Secondary - Primary - Correl Sci NOS - N0879
